US EditionModerna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts
Moderna receives $54 million to advance its bird flu vaccine to pivotal trials after a $760 million federal contract was canceled amid pandemic preparedness concerns.
- After the Department of Health and Human Services canceled a $760 million contract in May, Moderna secured $54 million to develop an mRNA H5 bird flu vaccine for pivotal trials.
- Public health officials say the avian H5 strain poses a significant pandemic risk, and the World Health Organization said studied bird flu vaccines reduce future pandemic likelihood while mRNA technology targets the 100-day goal.
- CEPI will bankroll a phase‑three trial for Moderna's H5 vaccine, which Moderna pledged to reserve 20% of production for low‑income countries at affordable prices.
- The trial is scheduled to start early next year, underscoring urgency because in a pandemic 'every day counts,' while some critics called the cancellation shortsighted, and HHS promised safe, effective vaccines.
- Dr. Richard Hatchett, CEO of CEPI, said pandemic influenza is a top threat to global health security, while mRNA technology aims to cut response times drastically for vaccine designers.
15 Articles
15 Articles
Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts
Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the funding that was cut off when the federal government cancelled hundreds of millions in contracts.
After HHS walks away from mRNA vaccine research, Moderna finds $54M lifeline
Moderna is getting $54 million to develop a bird flu vaccine after the U.S. government canceled a much larger contract. The Coalition for Epidemic Preparedness Innovations will fund a phase three trial for Modernas H5 bird flu vaccine.The Department of Health and Human Services canceled a $760 million contract with Moderna in May. The new funding will support the first mRNA vaccine for pandemic influenza to reach pivotal trials.Unlike traditiona…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
